Elucirem™ (Gadopiclenol)
MRI of CNS and body in adults & children from birth
Key Facts
Indication
MRI of CNS and body in adults & children from birth
Phase
Marketed
Status
Active - EU pediatric approval 2025
Company
About Guerbet
Guerbet S.A. is a global specialist in contrast media and solutions for medical imaging, with a mission encapsulated in its tagline 'Visibly Different.' The company has achieved a leading position through a century of innovation, most recently marked by the European approval of its half-dose MRI agent, Elucirem™, for use in children from birth. Its strategy focuses on advancing its core platform of gadolinium and iodinated agents, while navigating a challenging financial period to return to sustainable growth and profitability.
View full company profile